Insmed Inc (INSM)vsOncternal Therapeutics Inc (ONCT)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
ONCT
Oncternal Therapeutics Inc
$0.53
0.00%
HEALTHCARE · Cap: $1.56M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 27962% more annual revenue ($606.42M vs $2.16M). ONCT leads profitability with a 0.0% profit margin vs -2.1%. ONCT earns a higher WallStSmart Score of 43/100 (D).
INSM
Hold39
out of 100
Grade: F
ONCT
Hold43
out of 100
Grade: D
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
1.8% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : ONCT
The strongest argument for ONCT centers on Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : ONCT
The primary concerns for ONCT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while ONCT is a value play — different risk/reward profiles.
ONCT carries more volatility with a beta of 1.33 — expect wider price swings.
ONCT is growing revenue faster at 1.8% — sustainability is the question.
ONCT generates stronger free cash flow (-7M), providing more financial flexibility.
Bottom Line
ONCT scores higher overall (43/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Oncternal Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of cancer therapies for cancers with critical unmet medical needs. The company is headquartered in San Diego, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?